神经调节用于治疗中度至重度喘 - - 一项试点首次在人身上进行临床研究
Kurt Gehlsen1, Angelica Carrasco2, Jillian Hooghius2
1Spiro Medical, Inc, Belleair Bluffs, FL, USA.
概括
神经调节显著改善了患者的喘症状和生活质量,减少了药物需求和预防恶化. 这种创新的治疗方法没有显示任何不良事件,为喘管理提供了一个有希望的替代方案.
科学领域:
- 肺部医学 肺部医学
- 神经学 神经学
- 临床试验 临床试验
背景情况:
- 喘是一种慢性呼吸道疾病,影响全球数百万人.
- 目前的治疗方法通常需要长期服用药物,可能会产生副作用.
- 需要新的治疗方法来管理中度至重度喘.
研究的目的:
- 评估神经调节在中度至重度喘患者的安全性和有效性.
- 评估神经调节对喘控制,药物使用和生活质量的影响.
主要方法:
- 一个小型的,不受控制的,首次在人身上进行的临床研究.
- 纳入了11名中度至重度喘 (或喘与COPD) 的患者.
- 患者接受了永久脊髓刺激器,并在12个月内进行了随访.
主要成果:
- 91%的患者实现了>50%的喘药物减少.
- 百分之百的人报告了改善喘控制 (ACT>19) 和生活质量 (AQLQ).
- 没有报告与喘相关的急救访问或住院治疗;没有发生任何不良事件.
结论:
- 神经调节为中度至重度喘提供了安全有效的治疗方法.
- 它为症状和生活质量提供了临床上有意义的改善.
- 这种方法减少了对喘药物的需要和不良事件.
相关概念视频
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Antiasthma Drugs: Muscarinic Receptor Antagonists
468
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
468
Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
Antiasthma Drugs: Leukotriene Modifiers
489
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
489
Asthma-I: Introduction
2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Antiasthma Drugs: β2-Adrenoceptor Agonists
394
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
394


